Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.75 |
| ▸ | MAOA | P21397 | 2/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.75 |
| ▸ | MAPT | P10636 | 2/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.75 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | GOT1 | P17174 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.51 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydralazine SCHEMBL29484435 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MAOAPTGS1MAPTTDP1 | |
| Dihydralazine SCHEMBL149629 | 0.87 | ALDH1A1 (1.00) | ALDH1A1MAOAPTGS1MAPTTDP1 | |
| Dihydralazine SCHEMBL3462832 | 0.82 | ALDH1A1 (0.90) | ALDH1A1MAOAPTGS1MAPTTDP1 | |
| SCHEMBL25861219 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAOAPTGS1MAPTTDP1 | |
| SCHEMBL89446 | 0.79 | SMN1; SMN2 (0.58) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| Dihydralazine SCHEMBL2129435 | 0.78 | ALDH1A1 (0.72) | ALDH1A1MAOAPTGS1MAPTTDP1 | |
| SCHEMBL15721355 | 0.77 | ALDH1A1 (0.78) | ALDH1A1MAOAPTGS1MAPTTDP1 | |
| Ammonia Solution, Strong SCHEMBL27658861 | 0.77 | SMN1; SMN2 (0.56) | ALDH1A1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL31146711 | 0.75 | GOT1 (1.00) | ALDH1A1MAOAPTGS1MAPTTDP1 | |
| SCHEMBL19358618 | 0.75 | MAPT (0.75) | ALDH1A1MAOAPTGS1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106047-B2 | (4-Methoxyphenyl)-[3-(4-methoxyphenyl)-[1,2,4]triazolo[3,4-a]phthalazin-6-yl]-amine; phosphodiesterase inhibitors; septic shock or vascular edema; neoangiogenesis or inflammatory disease | NYCOMED GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20110136803-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2011-06-09 | — | — | US | disclosed |
| US-7851472-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-12-14 | — | — | US | disclosed |
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | NYCOMED GMBH (DE) | 2010-11-11 | — | — | US | disclosed |
| US-7671050-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-03-02 | — | — | US | disclosed |
| US-20090005372-A1 | Triazolophthalazines | ALTANA PHARMA AG (DE) | 2009-01-01 | — | — | US | disclosed |
| US-20080312225-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080280907-A1 | Triazolophthalazines | AALTANA PHARMA AG (DE) | 2008-11-13 | — | — | US | disclosed |
| WO-2002081474-A1 | TRIAZOLOPHTHALAZINE / QUINOLINE / ISOQUINOLINE DERIVATIVES WHICH ARE LIGANDS FOR GABA-A RECEPTORS CONTAINING THE ALPHA 5 SUBTYPE | MERCK SHARP & DOHME LIMITED (GB) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286140-A1 | TRIAZOLOPHTHALAZINES | PDE2A, PDE12, PDE3A | ALDH1A1 717/4885MAOA 386/4885PTGS1 134/4885 |
| US-20080280907-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | ALDH1A1 920/4885MAOA 442/4885PTGS1 351/4885 |
| US-20110136803-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | ALDH1A1 920/4885MAOA 442/4885PTGS1 351/4885 |
| US-20090005372-A1 | Triazolophthalazines | PDE2A, PDE12, PDE3A | ALDH1A1 717/4885MAOA 386/4885PTGS1 134/4885 |
| US-20080312225-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | ALDH1A1 920/4885MAOA 442/4885PTGS1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.